Replimune Group Sees Unusually High Options Volume (NASDAQ:REPL)

Replimune Group, Inc. (NASDAQ:REPL) was the recipient of some unusual options trading on Tuesday. Stock investors acquired 12,092 call options on the stock. This represents an increase of 142% compared to the average daily volume of 5,002 call options.

Insider Buying and Selling

In other Replimune Group news, Director Kapil Dhingra sold 3,169 shares of Replimune Group stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $10.40, for a total value of $32,957.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Sushil Patel sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $11.13, for a total transaction of $111,300.00. Following the completion of the transaction, the chief executive officer owned 333,576 shares in the company, valued at approximately $3,712,700.88. This represents a 2.91% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 25,625 shares of company stock valued at $257,607 over the last ninety days. Insiders own 5.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Readystate Asset Management LP increased its stake in shares of Replimune Group by 1,296.2% in the 3rd quarter. Readystate Asset Management LP now owns 2,621,012 shares of the company’s stock worth $10,982,000 after purchasing an additional 2,433,292 shares in the last quarter. Braidwell LP grew its holdings in Replimune Group by 550.3% during the third quarter. Braidwell LP now owns 2,750,092 shares of the company’s stock valued at $11,523,000 after purchasing an additional 2,327,205 shares during the period. Balyasny Asset Management L.P. increased its position in Replimune Group by 507.4% in the third quarter. Balyasny Asset Management L.P. now owns 2,628,100 shares of the company’s stock worth $11,012,000 after buying an additional 2,195,448 shares in the last quarter. Erste Asset Management GmbH raised its stake in shares of Replimune Group by 13,597.5% in the third quarter. Erste Asset Management GmbH now owns 1,630,000 shares of the company’s stock worth $7,074,000 after buying an additional 1,618,100 shares during the period. Finally, UBS Group AG grew its stake in shares of Replimune Group by 270.4% during the 3rd quarter. UBS Group AG now owns 901,630 shares of the company’s stock valued at $3,778,000 after acquiring an additional 658,233 shares during the period. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Stock Performance

Replimune Group stock traded up $0.03 during mid-day trading on Tuesday, reaching $8.45. 113,453 shares of the stock traded hands, compared to its average volume of 890,150. Replimune Group has a 12-month low of $2.68 and a 12-month high of $14.80. The business’s 50-day moving average is $9.60 and its 200-day moving average is $7.61. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.31 and a quick ratio of 6.31. The stock has a market capitalization of $662.45 million, a PE ratio of -2.45 and a beta of 0.72.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.03). As a group, sell-side analysts predict that Replimune Group will post -2.97 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently issued reports on REPL shares. HC Wainwright raised Replimune Group from a “neutral” rating to a “buy” rating and set a $12.00 price objective on the stock in a research report on Monday, October 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Replimune Group in a report on Monday, December 29th. Leerink Partners upgraded Replimune Group from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $3.00 to $13.00 in a report on Monday, October 20th. Piper Sandler raised Replimune Group from a “neutral” rating to an “overweight” rating and set a $13.00 target price for the company in a research report on Monday, October 20th. Finally, JPMorgan Chase & Co. raised shares of Replimune Group from an “underweight” rating to a “neutral” rating and set a $11.00 price target on the stock in a report on Monday, October 20th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Replimune Group has an average rating of “Moderate Buy” and an average target price of $9.75.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.